NFATC3

Across TCGA pan-cancer cohorts, NFATC3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NFATC3 data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher NFATC3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated NFATC3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SARC, and PRAD are the cancer types where NFATC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.826	.006	32	view →
SARC	DFS	Median	All	0.094	0.632	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
LUAD	OS	Median	All	0.324	0.677	.007	5	view →
KIRP	OS	Median	All	0.192	0.705	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NFATC3–UCEC (DFS)

Open the UCEC breakdown →